Heart failure & cardiomyopathies
SGLT2i Reduce Arrhythmic Events in Heart Failure Patients with Cardiac Implantable Electronic Devices
Authors' conclusion
In HFrEF carriers of ICD/CRT-D, the use of SGLT2i resulted in significant reduction of AA and VA events.
Study context
- Population
- HF with reduced ejection fraction (HFrEF) carriers of implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) followed by remote monitoringenrolled patients, 135 had arrhythmic events before SGLT2i therapy prescription
- Participants
- 198 carriers
- Comparison
- Incidence of AAs and VAs during 1 year preceding SGLT2i therapy initiation vs after 1 year of SGLT2i therapy
- Outcome
- Arrhythmic events recorded
- Follow-up
- 1 year
Methodological details1 year before and after SGLT2i therapy initiation, single centre (Policlinico Umberto I of Rome)
- 1 year before and after SGLT2i therapy initiation
- Single centre (Policlinico Umberto I of Rome)
Main finding
As reported in the abstract
Year before SGLT2i therapy initiation
1353
events
Year after SGLT2i initiation
354
events
- Reduction in events number after therapy initiation
- 73.8%
Further findings
AAs
Median
| Outcome | Year before SGLT2i therapy initiation | Year after SGLT2i initiation |
|---|---|---|
| Total arrhythmic episodes | 7 ([ ; ] [3;12]) | 1 ([ ; ] [0;4]) |
| VAs | 5.5 ([ ; ] [3;10]) | 0 ([ ; ] [0;2]) |
| AF episodes | 4 ([ ; ] [3;8]) | 0 ([ ; ] [0;3]) |
| NSVT | 4 ([ ; ] [2;8.75]) | 0 ([ ; ] [0;2]) |
| SVT | 3 ([ ; ] [2;4]) | 0 ([ ; ] [0;1]) |
- Total arrhythmic episodes: P value < 0.001
- AAs: P value < 0.001
- VAs: P value < 0.001
- Non-sustained ventricular tachycardia (NSVT): P value < 0.001
- Sustained ventricular tachycardia (SVT): P value < 0.001
Original publication
SGLT2i Reduce Arrhythmic Events in Heart Failure Patients with Cardiac Implantable Electronic Devices. ESC Heart Fail. Published 7 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →